Drugs / Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center
Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center
Cell therapy targets CD19 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07659704 | Oct 2026 → Oct 2027 expected | systemic lupus erythematosus | University of Sao Paulo | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07659704 ↗ |
| Action | Deplete | “The therapy is intended to achieve deep and sustained depletion of CD19-positive B cells implicated in the pathogenesis of systemic lupus erythematosus.” NCT07659704 ↗ |
| Modality | Cell therapy | “Autologous CD19-directed chimeric antigen receptor T (CAR-T) cells developed and manufactured at the Ribeirão Preto Blood Center” NCT07659704 ↗ |
| Route | Intravenous | “participants receive a single intravenous infusion of the autologous CAR-T cell product” NCT07659704 ↗ |
| Target | CD19 | “genetically modified ex vivo using a lentiviral vector to express a CD19-specific chimeric antigen receptor” NCT07659704 ↗ |